Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03079297 · ClinicalTrials.gov registry record · Phase 2
Rapid Antidepressant Effects of Leucine
A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT03079297 is a Phase 2 study that was terminated before completion, run by University of Texas Southwestern Medical Center. The registered enrollment target is 16 participants.
The verdict
NCT03079297, a Phase 2 study, was terminated before completion, sponsored by University of Texas Southwestern Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
This randomized double-blind placebo-controlled crossover study seeks to evaluate the antidepressant effect of L-leucine, an essential amino acid, in patients with Major Depressive Disorder (MDD).
Interventions
- OTHER Maltodextrin
- DRUG L-Leucine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2017-03-09 |
| Est. Completion | 2021-10-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03079297
The ClinicalTrials.gov registry entry for NCT03079297 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Maltodextrin is the first listed.
NCT03079297 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03079297 about?
NCT03079297 is a clinical study titled "Rapid Antidepressant Effects of Leucine". This randomized double-blind placebo-controlled crossover study seeks to evaluate the antidepressant effect of L-leucine, an essential amino acid, in patients with Major Depressive Disorder (MDD).
What is the current status of trial NCT03079297?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2017-03-09. Estimated completion is 2021-10-04.
What interventions are being tested in trial NCT03079297?
The interventions under investigation include: Maltodextrin (OTHER), L-Leucine (DRUG).
Who is sponsoring clinical trial NCT03079297?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.